Ionis Pharmaceuticals (IONS) Net Margin (2009 - 2026)

Ionis Pharmaceuticals' Net Margin history runs 18 years deep, the most recent figure standing at 37.6% for Q1 2026.

• In Q1 2026, Net Margin rose 7405.0% year-over-year to 37.6%; the TTM figure through Mar 2026 stood at 4.27% (up 6822.0% YoY), while the FY2025 annual figure was 40.58%, up 2388.0% from the prior year.
• Net Margin was 37.6% for Q1 2026 at Ionis Pharmaceuticals, down from 60.76% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 6177.55% in Q2 2025 to a low of 119.52% in Q1 2024.
• Historically, Net Margin has averaged 310.14% across 5 years, with a median of 45.92% in 2022.
• The sharpest annual moves came in 2022 and 2025: Net Margin slumped 8574 bps in 2022, then surged 620697 bps in 2025.
• A 5-year view of Net Margin shows it stood at 34.88% in 2022, then soared by 92 bps to 2.85% in 2023, then plunged by 1524 bps to 46.35% in 2024, then surged by 231 bps to 60.76% in 2025, then slumped by 162 bps to 37.6% in 2026.
• The last three Net Margin figures came in at 37.6% (Q1 2026), 60.76% (Q4 2025), and 82.06% (Q3 2025), per Business Quant data.